News

Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI
Mereo BioPharma Group plc's ORBIT study for setrusumab in osteogenesis imperfecta moves to final analysis by 2025. Click for ...
Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
Data from Orbit and Cosmic studies expected around the end of the yearNOVATO, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- ...
Fierce Biotech4d
Lack of early win for Ultragenyx, Mereo’s bone disorder med dents stock, but analysts keep faith
Analysts are keeping the faith in Ultragenyx’s brittle bone disease medicines despite the monoclonal antibody failing to score an early outright win in an ongoing phase 3 trail. | Analysts are keeping ...
The Week6d
Beyond the orbit: Shubhanshu Shukla’s final frontier of discovery on the ISS
As Axiom Mission 4 comes to a close, the International Space Station serves Group Captain Shubhanshu Shukla and the rest of ...
BioSpace4d
Ultragenyx, Mereo Plummet After Late-Stage Trial for Rare Genetic Disorder Appears To Fall Short
Partners Ultragenyx and Mereo BioPharma saw their stocks drop by 21% and 30%, respectively, after announcing that the Phase ...
Ultragenyx, Mereo in selloff after trial update on bone disorder therapy
Ultragenyx (RARE) stock and Mereo (MREO) stock are in selloff after a trial update on thier bone disorder therapy UX143. Read ...
Pharmabiz3d
Ultragenyx, Mereo BioPharma announce UX143 phase 3 Orbit study for osteogenesis imperfecta progressing to final analysis
Novato, California Friday, July 11, 2025, 18:00 Hrs [IST] ...
Zacks.com on MSN4d
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.
Ultragenyx Pharmaceutical Inc.: Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced that the randomized, placebo-controlled Phase ...
Investor's Business Daily on MSN4d
Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Disease
Ultragenyx and Mereo stocks crashed Thursday after their treatment for brittle bone disease missed its mark in a second ...
Asianet Newsable on MSN5d
Ultragenyx, Mereo Sink After Hours As Bone Drug Trial Continues Without Early Stop; Retail Traders Feel Selloff Is Overdone
Some users suggested that the market was overreacting to the update from Mereo BioPharma and Ultragenyx, with one describing ...
Ultragenyx stock plummets after OI drug study continues to final analysis
Investing.com -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) stock plummeted 33% after the company announced its Phase 3 Orbit study for UX143 (setrusumab) in osteogenesis imperfecta patients will ...